European Resistance Patterns in S pettenkoferi

Evidence

This multicenter PETTENK-OS study characterized genomic diversity and antimicrobial resistance in Staphylococcus pettenkoferi, an underrecognized coagulase-negative staphylococcus increasingly reported as a human pathogen. The collection comprised 61 clinical isolates from 17 hospitals in five European countries, obtained between 2012 and 2024, together with two reference strains. Only one isolate per patient and clinical episode was included, while duplicate and longitudinal isolates from the same patient were excluded. Most clinical isolates originated from blood cultures or bone and joint infections, so the collection is clinically oriented rather than a broad population sample. pmid:42748359

Investigators identified species using MALDI-TOF mass spectrometry and performed whole-genome sequencing. Antimicrobial susceptibility was assessed with disk diffusion and broth microdilution using 2025 EUCAST breakpoints. The work also used phylogenetic analyses and compared genotype with phenotype; comparisons of resistance across phylogenetic clades used Benjamini-Hochberg false-discovery-rate adjustment. These methods allow the report to place observed resistance phenotypes alongside genomic determinants and lineage structure, rather than treating susceptibility testing as the sole evidence stream. pmid:42748359

The most prominent phenotypic findings were that 22 isolates, or 35.4%, were multidrug-resistant; 18 isolates, or 28.6%, were methicillin-resistant; and nearly all isolates, 92.1%, were fosfomycin-resistant. Methicillin-resistant isolates were all assigned to subclade I-A and were mecA-positive within SCC mec type IV. The study also described susceptibility below 70% for cefoxitin, erythromycin, and levofloxacin, while reporting high susceptibility above 90% for vancomycin, teicoplanin, dalbavancin, aminoglycosides, oxazolidinones, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline. pmid:42748359

Genomic analysis separated the full set of clinical and reference isolates into two major clades. The authors reported multidrug-resistant lineages and described ceftobiprole- and daptomycin-resistant isolates across distinct clades. For daptomycin, resistant isolates carried mutations in walKR, cls1, and/or cls2. Together, the phylogenetic and genotype-phenotype findings indicate that resistance-associated features were distributed in identifiable lineages within this collection, while some findings also appeared across distinct clades. pmid:42748359

Analysis — Resistance landscape and interpretive scope

This is best read as a laboratory and genomic characterization study, not as an estimate of infection burden, transmission risk, treatment effectiveness, or patient prognosis. Its multicenter collection, episode-level exclusion of duplicates, sequencing, and paired phenotypic testing make it useful for describing resistance in the sampled clinical isolates. The clustering of methicillin-resistant isolates in one reported subclade provides a lineage-specific observation, whereas ceftobiprole- and daptomycin-resistant isolates in distinct clades indicates that the reported resistance landscape is not summarized by a single lineage alone. pmid:42748359

The resistance proportions are notable descriptive findings, but they do not themselves establish clinical significance. The report supplies susceptibility patterns and genomic correlates, not comparative patient outcomes, therapeutic benefit, or a clinical decision threshold. Likewise, a statistically adjusted analysis method was reported for clade comparisons, but no p-value, confidence interval, or effect estimate for the headline resistance proportions is supplied here. The appropriate conclusion is therefore limited: the sampled European clinical isolates showed substantial antimicrobial-resistance heterogeneity that supports continued microbiologic and genomic surveillance. pmid:42748359

Limitations

The collection does not define a broader population beyond the sampled clinical isolates and reference strains, so its observed patterns should not be treated as a population-wide prevalence estimate. The study’s clinical-source mix also means that results describe the isolates selected for this project rather than all colonizing or infecting S. pettenkoferi. This is an extraction and scope limitation, not evidence that the study failed to report other contextual information in its full publication. pmid:42748359

Genotype-phenotype concordance was partial or absent for some resistance determinants. The authors specifically stated that apparent discordance involving fosB-like variants and fosfomycin phenotype likely reflects recognized limitations of fosfomycin susceptibility testing for this species. Predicted high-level mupirocin resistance associated with mupA and predicted reduced susceptibility to quaternary ammonium compounds associated with qac were not phenotypically tested. Those gaps constrain interpretation of those particular genomic predictions and should not be generalized to the rest of the susceptibility results. pmid:42748359